Dr. Marianne K. Melnik, MD

Dr. Melnik practices at Corewell Health Grand Rapids Hospitals - Butterworth in Grand Rapids, Michigan, part of Corewell Health.

Dr. Melnik's NPI, 1629142658, was assigned on November 20, 2006. Dr. Melnik graduated from University of Chicago, Pritzker School of Medicine in 1983. Dr. Melnik holds Michigan license 4301067619.

Dr. Melnik's primary practice is Corewell Health Grand Rapids Hospitals - Butterworth, at 100 Michigan St NE, Grand Rapids, MI 49503 in Kent County. The practice phone is (616) 391-1774.

Dr. Melnik's primary practice is Corewell Health Grand Rapids Hospitals - Butterworth in Grand Rapids, Michigan, part of Corewell Health. The medical group on file is Corewell Health Medical Group West. Dmand AI also links Dr. Melnik to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melnik practices, 4 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Melnik's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Melnik is licensed in Michigan.

CMS data shows 90 Medicare services from Dr. Melnik across 3 procedure codes in 2024, all of them office visits, for 85 Medicare patients. Medicare paid $10,538 for them. Every service was in an office.

CMS counts 85 Medicare patients who saw Dr. Melnik in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have cancer, and 74% have high cholesterol. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Melnik's median patient age at 65, with 93% women.

In 2024, Dr. Melnik wrote 117 Medicare Part D claims for 56 patients. 99% of them were for generic drugs. CMS names the drug for 76 of them, across 2 drugs with 11 or more claims each, at $3,648 in total drug cost. In 2023, CMS named 102 claims across 3 drugs.

Dr. Melnik accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Dr. Melnik, published from 2010 to 2025. 2010 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Antineoplastic Agents and Antineoplastic Combined Chemotherapy Protocols. Dr. Melnik has published most often in Am J Surg. Dr. Melnik's most frequent co-authors are Mathew Hwayup Chung, MD, Supriya Gupta Mohile, MD and Gerald Paul Wright, MD.

Dmand AI links Dr. Melnik to 1 clinical trial. Conditions studied include Multiple Endocrine Neoplasia Type 1 and Multiple Endocrine Neoplasia.

CMS Open Payments shows 13 general payments to Dr. Melnik from 8 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 77% of the total. Hologic Inc paid the most, $1,139.

Dr. Melnik graduated from University of Chicago, Pritzker School of Medicine in 1983.